February 17, 2009 Vion Pharmaceuticals, announced today that it has filed a New Drug Application with the U.S. FDA for its lead oncology therapeutic Onrigin (laromustine) Injection as a single agent for remission induction treatment for patients sixty years of age or older with poor-risk acute myeloid leukemia.
The details can be read here.
No comments:
Post a Comment